SHPH Insider Trading

Insider Ownership Percentage: 39.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,912.22

Shuttle Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Shuttle Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shuttle Pharmaceuticals Share Price & Price History

Current Price: $0.70
Price Change: Price Decrease of -0.04 (-5.41%)
As of 12/12/2024 01:00 AM ET

This chart shows the closing price history over time for SHPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Shuttle Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2023Bette JacobsDirectorSell4,157$0.46$1,912.2227,064View SEC Filing Icon  
12/29/2022Hoek Michael VanderCFOSell2,243$1.60$3,588.803,852View SEC Filing Icon  
12/29/2022Peter DritschiloCOOSell3,820$1.60$6,112.006,560View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Shuttle Pharmaceuticals (NASDAQ:SHPH)

4.58% of Shuttle Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Shuttle Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/2/2023SG Americas Securities LLC16,899$33K0.0%N/A0.124%Search for SEC Filing on Google Icon
11/14/2022Hsbc Holdings PLC13,737$67K0.0%N/A0.103%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC17,048$78K0.0%N/A0.128%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Shuttle Pharmaceuticals logo
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Read More on Shuttle Pharmaceuticals

Today's Range

Now: $0.70
Low: $0.70
High: $0.75

50 Day Range

MA: $1.11
Low: $0.70
High: $1.87

52 Week Range

Now: $0.70
Low: $0.70
High: $4.95

Volume

39,659 shs

Average Volume

76,490 shs

Market Capitalization

$2.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals' top insider shareholders include:
  1. Bette Jacobs (Director)
  2. Peter Dritschilo (COO)
  3. Hoek Michael Vander (CFO)
Learn More about top insider investors at Shuttle Pharmaceuticals.